Larazotide acetate: designed to protect the intestinal barrier in celiac disease
An investigational, first-in-class oral peptide that acts locally in the small intestine to regulate tight junctions.
Larazotide acetate is an investigational, first-in-class oral gut-restricted tight junction regulator designed to help protect the intestinal barrier from the effects of gluten exposure in people with celiac disease, alongside a gluten-free diet. This eight-amino-acid peptide is designed to act locally in the small intestine by regulating tight junctions between intestinal cells. By helping maintain the intestinal barrier, larazotide is designed to reduce gluten-induced intestinal permeability and prevent downstream immune activation, inflammation, and intestinal injury.
Key design features
How larazotide is designed to work
- Gluten exposureTrigger
- Tight junction signalingResponse
- LarazotideDesigned to regulate tight junctions
- Reduced permeabilityBarrier function supported
- Upstream of immune activationBefore inflammation begins
Larazotide acetate is an investigational product that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any indication, and its safety and efficacy have not been established.